Cue Biopharma And Boehringer Ingelheim Announce Strategic Partnership To Develop And Commercialize First-in-Class Bispecific T Cell-Engaging B Cell Depletion Therapy CUE-501 For Autoimmune And Inflammatory Diseases, Aiming For Earlier Intervention And Lon